ライフサイエンスコーパス: partial remission

1 s had a complete response, and 1 patient had partial remission).

2 = .03), but not for remission (>/= very good partial remission).

3 d an objective response (13 complete and two partial remissions).

4 uxetan given as consolidation of complete or partial remission.

5 pe), four with incomplete CR, and three with partial remission.

6 , additional end points included complete or partial remission.

7 on [CR(u)] and 11 patients (27%) achieving a partial remission.

8 tients attained a complete remission and 1 a partial remission.

9 finition and follow-up of emerging mania and partial remission.

10 1 additional patient with HES has achieved a partial remission.

11 ents achieved and sustained CR, 3 nCR, and 4 partial remission.

12 d a complete remission, and 43 percent had a partial remission.

13 90% of this sample were either in full or in partial remission.

14 d dose level, 1 patient obtained a very good partial remission.

15 achieved complete remission and two achieved partial remission.

16 plete remission of diabetes and 5 (6.4%) had partial remission.

17 ansfer in two patients, one of whom showed a partial remission.

18 This patient is in an ongoing very good partial remission.

19 ith mantle cell lymphoma obtained an ongoing partial remission.

20 residual disease achieved either complete or partial remission.

21 ssion (CR), and 17 patients (29%) achieved a partial remission.

22 decreased among those achieving complete or partial remission.

23 nistration, 65 patients achieved complete or partial remission.

24 st 4 years of follow-up achieved complete or partial remission.

25 for more than 6 months, and three achieved a partial remission.

26 t recovery, and one (FLT3 wild-type AML) had partial remission.

27 te hematologic remission, and one achieved a partial remission.

28 One patient experienced an NCI WG partial remission.

29 rable disease, 10 (31%) achieved complete or partial remission.

30 CRs without platelet recovery (CRp), and six partial remissions.

31 aneous complete remission and 2 patients had partial remissions.

32 cluded six complete remissions (CRs) and two partial remissions.

33 26.1%), with four complete responses and six partial remissions.

34 40%; all responses in patients with CLL were partial remissions.

35 94% included 74% complete remissions and 20% partial remissions.

36 ee with non-small-cell lung cancer, achieved partial remissions.

37 (JAK) inhibitors, do not induce complete or partial remissions.

38 rved 9 of 19 complete remissions and 3 of 19 partial remissions.

39 of 25 (71%) complete remissions and 10 (29%) partial remissions.

40 uding 12% complete responses and 12% nodular partial remissions.

41 was 73% with 55% complete remissions and 18% partial remissions.

42 s excellent: 90.2% complete remission, 3.92% partial remission, 1.96% stable disease, 1.96% disease-r

43 a complete remission (2%), and five achieved partial remission (10%).

44 Three of 26 evaluable patients achieved partial remission (11.5%) and 13 patients achieved stabl

45 d one complete remission (21 months) and one partial remission (14 months) at the 480-mg/m(2)-dose le

46 Two complete remissions and one partial remission (18%) were observed in 16 assessable p

47 s assessable for disease response, one had a partial remission (2 months), one has had stable disease

48 achieved objective response, including four partial remissions (2- to 6-month duration) and six comp

49 ctive responses (hematologic improvement, 3; partial remission, 2; or complete remission, 1) were see

50 P = .05), and remission rate (>/= very good partial remission; 23% v 47%, respectively; P = .02).

51 17 with complete remission (57%) and 10 with partial remission (33%).

52 were seen in 12 of 35 assessable patients (1 partial remission, 4 minor/mixed responses and 7 with st

53 SF in 77% of complete remission or very good partial remission, 45% of primary refractory, 25% of sec

54 assessable for response, 17 (71%) achieved a partial remission (46%) or complete remission (25%).

55 ed partial responses, with one in continuing partial remission 47 months after therapy.

56 chieved in 23 patients (18%), 36 (27%) had a partial remission, 55 (42%) had stable disease, and 8 pa

57 , 6, 7.4, and 9.3 GBq, respectively, were in partial remission 8 wk after completing all 3 cycles.

58 reater than 40% of patients with complete or partial remission, a significant 5-year survival benefit

59 ved remission, and 21 patients (47%) reached partial remission after 1 cycle of BCDT (mean followup 3

60 Rates of partial remission after 2 weeks of treatment with fluoxe

61 in first complete remission and 13 in first partial remission after conventional therapy.

62 chronic lymphocytic leukaemia in complete or partial remission after second-line or third-line treatm

63 progressed during paclitaxel treatment had a partial remission after the addition of cyclosporin A (r

64 Thirty-four (19%) of 184 had a partial remission and 55 (31%) of 184 had no response or

65 achieved in 25% of 177 patients, and nodular partial remission and partial remission were achieved in

66 The third patient had an objective partial remission and relapsed at 12 months after infusi

67 of recurrence-free survival after achieving partial remission and remained significant after adjustm

68 % confidence interval [CI], 33-62), with 22% partial remissions and 25% MR.

69 When partial remissions and anxiety disorder diagnoses classi

70 hieved complete remission, 14 of 51 achieved partial remission, and 1 of 51 had progressive disease.

71 eved a complete response (CR), one a nodular partial remission, and 10 patients a partial remission (

72 ) achieved complete remission, four achieved partial remission, and 21 failed therapy.

73 ssion (CR), 12% of patients (n = 8) achieved partial remission, and 9% of patients (n = 6) died of in

74 Partial response, very good partial remission, and complete response were documented

75 but best monotherapy responses are typically partial remission, and patients must remain on treatment

76 Patients with recurrent disease, partial remission, and progressive disease were retreate

77 Probabilities of full remission, partial remission, and relapse during this year were exa

78 he patients (N = 28) demonstrated at least a partial remission, and there was no difference between t

79 on as persistent proteinuria <0.3 g/24 h and partial remission as persistent proteinuria <3 g/24 h, e

80 as defined as minimal or no BDD symptoms and partial remission, as meeting less than full DSM-IV crit

81 h FC offers patients who achieve complete or partial remission, as well as those who have fludarabine

82 A secondary end point was partial remission at 24 weeks.

83 and 28 LAGB participants (28.6%) experienced partial remission at 3 years.

84 n patients transplanted in first complete or partial remission at 4 years (66% vs 36%; P = .062).

85 sed treatment was significantly superior for partial remission at EOT but not at follow-up.

86 ailure-free survival (defined as less than a partial remission at the end of induction, relapse, prog

87 one patients (70%) were in first complete or partial remission at the time of the ASCT.

88 6 were in complete remission, and 8 were in partial remission before allo-HCT with 12 grafts from un

89 clinically: 59% and 88% attained complete or partial remission by 12 and 24 months, respectively, com

90 not allow further separation of patients in partial remission by risk of recurrence (P=.9).

91 sion for 3 to 21 months, and two patients in partial remission continue to improve after 14 and 19 mo

92 Patients in complete/very good partial remission (CR/VGPR) after P6 received myeloablat

93 (22%), giving a complete remission/very good partial remission (CR/VGPR) rate of 78%.

94 th 2 patients achieving partial response and partial remission cytolytic response, respectively.

95 on in 72%, nodular partial remission in 10%, partial remission due to cytopenia in 7%, and partial re

96 artial remission due to cytopenia in 7%, and partial remission due to residual disease in 6%.

97 over 30% of children underwent a complete or partial remission during the 2.5 years of therapy, but t

98 h a homozygous ADCK4 frameshift mutation had partial remission following CoQ10 treatment.

99 Of the 12 patients, 1 had partial remission for 1 y, another had a minor response

100 ission, surgical free of disease, continuous partial remission for 2+ years), time to treatment failu

101 ed complete remissions and 26% have achieved partial remissions for an overall response of 83%.

102 Partial remission (for comparison purposes) was defined

103 The overall response rate (complete or partial remissions) for all 26 dogs was 46% (12 of 26),

104 In addition, 48% of patients achieved a partial remission, for an overall response rate of 65% (

105 was most evident for patients in complete or partial remission (good risk; GR) at ASCT.

106 Tumor responses included partial remission (>/= 50% reduction in tumor volume) in

107 modulatory drugs-patients who do not achieve partial remission have a significantly shorter overall s

108 Three patients achieved and continue in partial remission (hemoglobin at least 10 g/dL without t

109 95%, with complete remission in 72%, nodular partial remission in 10%, partial remission due to cytop

110 disclosed a complete tumor remission in 3, a partial remission in 12 and a stable disease in 6 patien

111 nse evaluation ((68)Ga-PSMA PET/CT) revealed partial remission in 14, stable disease in 2, and progre

112 ion occurred in 49 of the 65 patients (75%), partial remission in 15 (23%), and no response in 1 (2%)

113 disease were complete remission in 43 (58%), partial remission in 19 (26%), and no response in 12 (16

114 colitis were complete remission in 34 (54%), partial remission in 19 (30%), and no response in 10 (16

115 treated with (177)Lu-DOTA-JR11, resulting in partial remission in 2 patients, stable disease in 1 pat

116 as achieved in 72 of 99 patients (72.7%) and partial remission in 24 of 99 patients (24.2%).

117 Contrast-enhanced CT revealed partial remission in 5, stable disease in 13, and progre

118 nsplantation (ASCT) during first complete or partial remission in 52 patients with poor-risk aggressi

119 tion in lupus in the last year, complete and partial remission in lupus nephritis has been achieved i

120 mens, with occasional complete remission and partial remission in some patients.

121 nd EBV-CTLs each induced durable complete or partial remissions in 73% and 68% of treated patients in

122 uced complete remissions in 4 of 19 mice and partial remissions in the remainder.

123 New definitions of complete and partial remission incorporate clinical, hematological, a

124 mplete haematological recovery, and 25 (10%) partial remission INTERPRETATION: Gilteritinib had a fav

125 eveloped an acute phase of EAE followed by a partial remission, middle-age males suffered severe chro

126 ponse to CLL therapy was complete (n = 4) or partial remission (n = 1) and stable disease (n = 1).

127 tocol entry: complete remission or very good partial remission (n = 33), primary refractory (n = 33),

128 Complete (n=5) or partial remission (n=5) was achieved in T-cell acute lym

129 tients responded (complete remission, n = 2; partial remission, n = 1).

130 Partial remission occurred in 21 of the 71 patients (29.

131 A complete or partial remission occurred in 7 patients (21%), with a m

132 Response (complete/partial remission) occurred in 26 of the 28 patients (93

133 documented in 36%, with five complete and 11 partial remissions, occurring after a median of 6 weeks

134 come was a combined end point of complete or partial remission of proteinuria at 6 months.

135 Complete and partial remission of proteinuria within 12 months of dis

136 was associated with a greater likelihood of partial remission of type 2 diabetes compared with diabe

137 ved complete remissions (CRs), four achieved partial remissions, one had stable lymphoma, and two wer

138 sion (CR) was achieved in 22 patients (14%); partial remission or hematologic improvement occurred in

139 redict patients who would attain complete or partial remission or no-response to first-line chemother

140 Disease control rates (complete or partial remission or stable disease in patients with for

141 f these, 66% maintained a complete and 34% a partial remission over the study period.

142 and included one complete remission and four partial remissions (overall response rate, 11.6%; 95% co

143 were highly expressed in non-responders and partial remission patients than in complete remission pa

144 If in complete or partial remission, patients proceeded to consolidation w

145 Three patients (11%) achieved a partial remission (PR) (durations, 7, 8, and 19 weeks) a

146 Six patients (15%) achieved a partial remission (PR) (durations: 8, 14, 18, 28, 56, an

147 2) relapse after first transplant in 20, (3) partial remission (PR) after first transplant in eight,

148 atients with aGHVD were nonresponsive and in partial remission (PR) after steroids, respectively, and

149 All responders had at least a partial remission (PR) after the first therapy dose of (

150 Patients who did not achieve at least a partial remission (PR) after two courses or whose diseas

151 erwent ABMT in first complete remission (CR)/partial remission (PR) following CHOP induction.

152 Complete remission (CR) was achieved in 70%, partial remission (PR) in 18%, nodular PR in 3%, for an

153 f complete remission (CR) in 51% (24 of 47), partial remission (PR) in 38% (1 8 of 47), and stable di

154 (CR) in 2 patients with Hodgkin disease and partial remission (PR) in a patient with refractory mant

155 ete remission in three patients (11.5%), and partial remission (PR) in three patients (11.5%).

156 ission (CR) of pancreatic cancer (10 mg/m2), partial remission (PR) of malignant melanoma in two pati

157 script evaluates complete remission (CR) and partial remission (PR) of proteinuria as surrogate end p

158 Being in partial remission (PR) or complete remission (CR) at HCT

159 complete remission (CR) rate was 50% and the partial remission (PR) rate was 37%.

160 The complete remission (CR) plus partial remission (PR) rate was 47% (95% confidence inte

161 All 5 patients achieving a clinical partial remission (PR) studied by cPCR were positive.

162 d partial remission (VGPR), and nine were in partial remission (PR), according to criteria from Inter

163 ; 5 are in complete remission (CR), 2 are in partial remission (PR), and 10 have stable or progressiv

164 esponse categories: complete remission (CR), partial remission (PR), and clinical improvement (CI).

165 in complete remission (CR), five achieved a partial remission (PR), and four had stable disease (SD)

166 We defined complete remission (CR), partial remission (PR), and relapse as proteinuria </=0.

167 n very good partial remission (VGPR), one in partial remission (PR), and two had microscopic foci in

168 nodular partial remission, and 10 patients a partial remission (PR), for an overall response (OR) rat

169 eved complete remission (CR), and 3 achieved partial remission (PR), for an overall response rate of

170 Of four patients who achieved a partial remission (PR), one remains progression-free at

171 Secondary end points were partial remission (PR), symptoms, compliance, esophageal

172 Six of 18 assessable patients had a partial remission (PR), with a median time to disease pr

173 ll response rate was 76% with 60% CR and 16% partial remission (PR).

174 , 40 (80%) achieved CR, and 9 (18%) achieved partial remission (PR).

175 remission (CR); 18 patients (21%) achieved a partial remission (PR); and 1 patient's response was una

176 Partial remission (PR; defined as no active bleeding, FV

177 ion (CR), one unconfirmed CR (CRu), and four partial remissions (PR) among patients with follicular n

178 three complete remissions (CRs; 8%) and five partial remissions (PR; 14%); response to melphalan (n =

179 verall response rate (complete response plus partial remission [PR] plus minimal response [MR]) was 7

180 n first response (complete remission [CR] or partial remission [PR]) with poor prognostic features, w

181 mantle cell non-Hodgkin lymphoma (NHL) (CR + partial remission [PR]), and high-grade NHL-CR had the l

182 teratoma-positive primary tumor, resectable partial remission [PR]), n = 90; group D [serologic CR,

183 d complete remission [CR] and 3 patients had partial remission [PR]).

184 rovement rate (OIR: complete remission [CR], partial remission [PR], marrow CR [mCR], or hematologic

185 m remission status (complete remission [CR], partial remission [PR], no remission [NR]).

186 n = 17; 75% complete remissions [CR] and 10% partial remissions [PR]), whereas 3 patients had progres

187 n (complete remission) or relatively benign (partial remission) prognosis.

188 responses were 1 complete remission (CR), 6 partial remissions (PRs), and 5 patients with stable dis

189 6%) complete remissions (CRs) and 12 (26.6%) partial remissions (PRs), for a CR plus PR rate of 33.3%

190 s (CRs plus unconfirmed CRs [CRu's]) and 23% partial remissions (PRs).

191 ematologic recovery [CRi]) and 13 (17%) with partial remissions (PRs).

192 ORR was 41% (8 complete remissions [CRs], 6 partial remissions [PRs]), and ORR was 54% in AITL (5 CR

193 The partial remission rate (PR) after two cycles of DTPACE w

194 te was 70% (95% CI, 63% to 76%), the nodular partial remission rate was 10%, and the partial remissio

195 ular partial remission rate was 10%, and the partial remission rate was 15%, for an overall response

196 Secondary outcome measures included partial remission rates (>85% of expected weight for hei

197 Long-term complete and partial remission rates were 24% and 26%, respectively,

198 Partial remission rates were 39%, 70%, and 83% after 1,

199 Patients in complete remission or partial remission received six reinduction courses, alte

200 with IIS resistance, complete remission, and partial remission, respectively; 27% in children with a

201 ries are listed: complete remission (CR) and partial remission signify treatment effects that are con

202 Anti-FVIII IgA-positive patients achieved partial remission similar to anti-FVIII IgA-negative pat

203 ver 11 to 23 months after treatment; 1 had a partial remission that persisted for 12 months; 1 has ha

204 year complete clinical remission, and 3% had partial remission; the other 3% developed chronic migrai

205 ints included overall response (complete and partial remission), time to overall response, and advers

206 Of the patients with partial remission to protocol treatment, 8 achieved remi

207 percent of patients had achieved less than a partial remission to their most recent therapy and would

208 chieved complete remission, 8 (29%) achieved partial remission (treatment eventually failed in 4 of t

209 ogic normalization (HN; complete remission + partial remission + trilineage hematological improvement

210 ated with 2-CdA, and all achieved at least a partial remission; two of these have already relapsed wi

211 One patient had a partial remission; two others had a reduction in blasts

212 omplete remission (CR), 12 were in very good partial remission (VGPR), and nine were in partial remis

213 in complete remission CR, eight in very good partial remission (VGPR), one in partial remission (PR),

214 om BDD was only 0.09, and the probability of partial remission was 0.21.

215 Partial remission was a change from a BILAG A or B score

216 Complete remission or partial remission was achieved in 247 patients (76%).

217 Partial remission was defined as a reduction in endoscop

218 Partial remission was defined as independence from trans

219 on was demonstrated in 34 patients (44%) and partial remission was demonstrated in 39 patients (50%).

220 Although the cumulative incidence of partial remission was lower in the Rtx group, rates of c

221 The percentage in remission versus partial remission was not statistically significant betw

222 A partial remission was seen by CT 1 mo after the first ra

223 20% improvement in 5 of 6 domains, and ASAS partial remission were achieved by 61%, 44%, and 56% of

224 patients, and nodular partial remission and partial remission were achieved in 16% and 32% of patien

225 Complete remission (CR) and partial remission were achieved in 55% and 15% of patien

226 ansplantation in first or second complete or partial remission were eligible.

227 Three complete remissions and one partial remission were observed in 30 assessable AML pat

228 ymphoma, and four of the six patients with a partial remission were positron emission tomography nega

229 h TRD who were moderately depressed or BD in partial remission were randomized to 8 weekly EPO (40,00

230 10% to 17% of azacitidine-treated patients; partial remissions were rare; 23% to 36% of patients had

231 a significantly higher rate of complete and partial remissions, while in first-line therapy a signif

232 ine, 11 had a complete remission and 2 had a partial remission with BL22.

233 on soon after the induction of a complete or partial remission with conventional-dose chemotherapy do

234 FL who achieved either complete or very good partial remission with salvage chemotherapy were randoml

235 atients (33%) achieved a major response (all partial remissions), with a median time to response of 3

236 Four patients achieved partial remission, with a >50% reduction in the glucocor

237 in 17 patients (3 complete remissions and 14 partial remissions), yielding an intent to treat respons